Real-world data reveals outcomes of tucatinib combo after T-DXd in HER2+ breast cancer
NCT ID NCT06961331
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 22 times
Summary
This study looked at medical records of 86 people with HER2+ metastatic breast cancer to see how well a three-drug combination (tucatinib, trastuzumab, and capecitabine) worked after they had already received a treatment called T-DXd. The goal was to measure things like time until the next treatment or death. The study did not give any new treatments but instead analyzed existing data to understand real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HER2+ ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.